Cancer Immunotherapy Stocks List

Cancer Immunotherapy Stocks Recent News

Date Stock Title
May 10 ALXO ALX Oncology Holdings Inc (ALXO) Q1 2024 Earnings Analysis: A Detailed Look at Financials and ...
May 10 RCUS Arcus Biosciences Surpasses Analyst Revenue Forecasts in Q1 2024
May 10 RCUS Arcus Biosciences First Quarter 2024 Earnings: Beats Expectations
May 9 ALXO ALX Oncology reports Q1 results
May 9 ALXO ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 9 RCUS Arcus Biosciences, Inc. (NYSE:RCUS) Q1 2024 Earnings Call Transcript
May 9 RCUS Arcus Biosciences Inc (RCUS) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
May 9 RCUS Arcus Biosciences, Inc. (RCUS) Q1 2024 Earnings Call Transcript
May 8 RCUS Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Tops Revenue Estimates
May 8 RCUS Arcus Biosciences GAAP EPS of -$0.05 beats by $0.92, revenue of $145M beats by $116.23M
May 8 RCUS Arcus Biosciences Reports First-Quarter 2024 Financial Results and Provides a Pipeline Update
May 8 BCAB BioAtla to Participate in the Citizens JMP Life Sciences Conference
May 7 RCUS Arcus Biosciences Q1 2024 Earnings Preview
May 7 ALXO ALX Oncology Appoints Allison Dillon as Chief Business Officer
May 7 BCAB BioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024
May 7 ACET Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference
May 6 BCAB BioAtla announces FDA clearance of ind application for its treatment of multiple tumors
May 6 BCAB BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors
Cancer Immunotherapy

Cancer immunotherapy (sometimes called immuno-oncology) is the artificial stimulation of the immune system to treat cancer, improving on the system's natural ability to fight cancer. It is an application of the fundamental research of cancer immunology and a growing subspecialty of oncology. It exploits the fact that cancer cells often have tumor antigens, molecules on their surface that can be detected by the antibody proteins of the immune system, binding to them. The tumor antigens are often proteins or other macromolecules (e.g. carbohydrates). Normal antibodies bind to external pathogens, but the modified immunotherapy antibodies bind to the tumor antigens marking and identifying the cancer cells for the immune system to inhibit or kill.

Browse All Tags